Induction of cytotoxic T lymphocytes with dendritic cells transfected with human papillomavirus E6 and E7 RNA: Implications for cervical cancer immunotherapy

Journal of Immunotherapy

Volumn 23, Issue 4, 2000, Pages 412-418

  Thornburg, Courtney ^a   Boczkowski, David ^a   Gilboa, Eli ^a   Nair, Smita K ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Cancer Vaccine; Cervical Cancer; Dendritic Cells; Human Papillomavirus; RNA

Indexed keywords

ONCOPROTEIN; VIRUS RNA;

ARTICLE; CANCER IMMUNOTHERAPY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; UTERINE CERVIX CANCER; WART VIRUS;

CYTOTOXICITY TESTS, IMMUNOLOGIC; DENDRITIC CELLS; FEMALE; HUMANS; IMMUNOTHERAPY, ADOPTIVE; ONCOGENE PROTEINS, VIRAL; PEPTIDES; REPRESSOR PROTEINS; RNA, VIRAL; T-LYMPHOCYTES, CYTOTOXIC; TRANSFECTION; TUMOR CELLS, CULTURED; UTERINE CERVICAL NEOPLASMS;

EID: 0033947945     PISSN: 10538550     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002371-200007000-00004     Document Type: Article

References (35)

1. Braly P. Preventing cervical cancer. Nat Med 1996;2:749-51.
2. Stern PL. Immunity to human papillomavirus-associated cervical neoplasia. Adv Cancer Res 1996;69:175-211.
3. Stanley M. Papillomavirus: biology and clinical implication for immunotherapy. Mol Med Today 1997;3:239-40.
4. Suzich JA, Ghim S-J, Palmer-Hill FJ, et al. Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas. Proc Natl Acad Sci USA 92:1995:11553-7.
5. Wilczynski SP, Pearlman L, Walker J. Identification of HPV-16 early genes retained in cervical carcinomas. Virologv 1988;166: 624-7.
6. Chen L, Thomas EK, Hu S-L, Hellström I, Hellström KE. Human papillomavirus type 16 nucleoprotein E7 is a tumor rejection antigen. Proc Natl Acad Sci USA 1991;88:110-14.
7. Chen L, Mizuno MT, Singhal MC, et al. Induction of cytotoxic T lymphocytes specific for a syngeneic tumor expressing the E6 oncoprotein of human papillomavirus type 16. J Immunol 1992; 148:2617-21.
8. Alloub MI, Barr BBB, McLaren KM, Smith IW, Bunney MH, Smart GE. Human papillomavirus infection and cervical intraepithelial neoplasia in women with renal allografts. BMJ 1989;298: 153-60.
9. Laga M, Icenogle JP, Marsella R, et al. Genital papillomavirus infection and cervical dysplasia-opportunistic complications of HIV infection. Int J Cancer 1992;50:45-54.
10. Benton C, Shahidullah H, Hunter JAA. Human papillomavirus in the immunosuppressed. Papillomavirus Report 1992;3:23-6.
11. Greenberg PD. Adoptive T cell therapy of tumors: mechanisms operative in the recognition and elimination of tumor cells. Adv Immunol 1991;49:281-355.
12. York IA, Rock KL. Antigen processing and presentation by the class I major histocompatibility complex. Annu Rev Immunol 1996;14:369-96.
13. Stauss HJ, Davies H, Sadovnikova E, Chain B, Horowitz H, Sinclair C. Induction of cytotoxic T lymphocytes with peptides in vitro: identification of candidate T-cell epitopes in human papilloma virus. Proc Natl Acad Sci USA 1992;89:7871-5.
14. Ressing ME, Sette A, Brandt RMP, et al. Human CTL epitopes encoded by human papillomavirus type 16 E6 and E7 identified through in vivo and in vitro immunogenicity studies of HLA-A *0201-binding peptides. J Immunol 1995;154:5934-42.
15. Ressing ME, van Driel WJ, Celis E, et al. Occasional memory cytotoxic T-cell responses of patients with human papillomavirus type 16-positive cervical lesions against a human leukocyte antigen-A *0201-restricted E7-encoded epitope. Cancer Res 1996;56: 582-8.
16. Borysiewicz K, Fiander A, Nimako M, et al. A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer. Lancet 1996;346:1523-7.
17. Stellar, MA, Gurski KJ, Murakami M, et al. Cell-mediated immunological responses in cervical and vaginal cancer patients immunized with a lipidated epitope of human papillomavirus type 16 E7. Clin Cancer Res 1998;4:2103-9.
18. Lin K-Y, Guarnier FG, Staveley-O'Carroll KF, et al. Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res 1996;56:21-6.
19. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998;392:245-52.
20. Schuler G, Steinman RM. Dendritic cells as adjuvants for immunemediated resistance to tumors. J Exp Med 1997;186:1183-7.
21. Macatonia SE, Taylor PM, Knight SC, Askonas BA. Primary stimulation by dendritic cells induces antiviral proliferative and cytotoxic T cell responses in vitro. J Exp Med 1988;169:1255-64.
22. Nair S, Zhou F, Reddy R, Huang L, Rouse BT. Soluble proteins delivered to dendritic cells via pH-sensitive liposomes induce primary cytotoxic T lymphocyte responses in vitro. J Exp Med 1992; 175:609-12.
23. Rouse RJD, Nair SK, Lydy SL, Bowen JC, Rouse BT. Induction in vitro of primary cytotoxic T-lymphocytes responses with DNA encoding herpes simplex virus proteins. J Virol 1994;68:5685-9.
24. Mehta-Damani A, Markowicz S, Engleman EG. Generation of antigen-specific CD8+ CTLs from naive precursors. J Immunol 1994;153:996-1003.
25. Boczkowski D, Nair S, Snyder D, Gilboa E. Dendritic cells pulsed with RNA are potent antigen presenting cells in vitro and in vivo. J Exp Med 1996;184:465-72.
26. Porgador A, Snyder D, Gilboa E. Induction of antitumor immunity using bone marrow-generated dendritic cells. J Immunol 1996;156: 2918-26.
27. Zitvogel L, Mayordomo JI, Tjandrawan T, et al. Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines. J Exp Med 1996;183:87-97.
28. Paglia P, Chiodoni C, Rodolfo M, Colombo MP. Murine dendritic cells loaded in vitro with soluble protein prime CTL against tumor antigen in vivo. J Exp Med 1996;183:317-22.
29. Huang AYC, Golumbek P, Ahmadzadeh M, Jaffee E, Pardoll D, Levitsky D. Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. Science 1994;264:961-5.
30. Ashley DM, Faiola B, Nair S, Hale LP, Bigner DP, Gilboa E. Bone marrow-generated dendritic cells pulsed with tumor extracts or tumor RNA induce antitumor immunity against central nervous system tumors. J Exp Med 1997;186:1177-82.
31. Ossevoort MA, Feltkamp MCW, van Veen KJH, Melief CJM, Kast WM. Dendritic cells as carriers for a cytotoxic T-lymphocyte epitope-based peptide vaccine in protection against a human papillomavirus type 16-induced tumor. J Immunother 1995;18:86-94.
32. Bakker ABH, Marland G, de Boer AJ, et al. Generation of antimelanoma cytotoxic T lymphocytes from healthy donors after presentation of melanoma-associated antigen-derived epitopes by dendritic cells in vitro. Cancer Res 1995;55:5330-4.
33. Murakami M, Gurski KJ, Marincola FM, Ackland J, Stellar MA. Induction of specific CD8+ T-lymphocyte responses using a human papillomavirus-16 E6/E7 fusion protein and autologous dendritic cells. Cancer Res 1999;59:1184-7.
34. Nair SK, Boczkowski D, Morse M, Cumming RI, Lyerly HK, Gilboa E. Induction of primary, carcinoembryonic antigen (CEA)-specific cytotoxic T lymphocytes in vitro using human dendritic cells transfected with RNA. Nat Med 1998;16:364-9.
35. Romani N, Gruner S, Brang D, et al. Proliferating dendritic cell progenitors in human blood. J Exp Med 1994;180:83-93.